论文信息 - Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). - 字舞流文

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

D. Schadendorf | P. Ascierto | E. Lipson | F. Hodi | H. Tawbi | A. Arance | H. Gogas | K. Simonsen | J. Grob | P. Rutkowski | G. Long | S. Dalle | C. Lao | J. Menezes | L. Matamala | Shivani Srivastava | Mena Abaskharoun | Bin Li | E. C. Gutiérrez